Eiger BioPharmaceuticals

October 20, 2016October 20, 2016

First Patient in Phase 2 Trial Receives Lambda as Therapy for Hepatitis D Virus Infection

Hepatitis D, News

Eiger BioPharmaceuticals has dosed the first patient in a Phase 2 clinical trial evaluating Lambda (pegylated interferon lambda 1a) monotherapy for the treatment of chronic hepatitis delta virus (HDV) infection. Lambda is ... Read more

April 7, 2016April 7, 2016

Eiger BioPharma to Present Its Hepatitis Delta Virus Development Program at EASL Meeting

News

Eiger BioPharmaceuticals announced that studies from its Hepatitis Delta Virus (HDV) development program will be presented at the upcoming European Association for the Study of the Liver (EASL) conference April 13-17 in Barcelona, Spain. Also, interim ... Read more

July 23, 2015July 23, 2015

Eiger BioPharmaceuticals Publishes Clinical Results of Lonafarnib in Hepatitis Delta Virus

News

Eiger BioPharmaceuticals Incorporated, a privately held biotechnology company focused on the research, development and commercialization of innovative therapies in viral hepatitis, recently announced their latest data on the first Phase 2a clinical ... Read more

January 19, 2015January 19, 2015

EB Pharma to Start Hepatitis D Therapy Study with Janssen

News

A subsidiary of Eiger BioPharmaceuticals, Inc., EB Pharma, LLC., has announced the execution of an agreement with Janssen Pharmaceutical NV, focused on the exclusive licensing of tipifarnib, a potential new therapy for the ... Read more